We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HALO icon
26
CALL
Halozyme
HALO
$9.9B
$8.8M 0.58%
6,867
+3,619
+111% +$48.3K
SIOX
27
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.64M 0.57%
466
+11
+2% +$1.93K
KITE
28
PUT
DELISTED
Kite Pharma, Inc.
KITE
$8.2M 0.54%
791
+500
+172% +$40.8K
SGEN
29
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$7.46M 0.49%
1,442
+752
+109% +$47.8K
TSRO
30
DELISTED
TESARO, Inc.
TSRO
$7.19M 0.47%
+51,426
New +$7.45M
UTHR icon
31
United Therapeutics
UTHR
$26.1B
$6.89M 0.45%
53,116
+35,774
+206% +$4.46M
ALXN
32
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
$6.69M 0.44%
550
– –
IONS icon
33
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$6.58M 0.43%
1,293
-18
-1% -$838
IONS icon
34
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$6.41M 0.42%
1,259
-1,264
-50% -$58.9K
AMRN
35
CALL
Amarin Corp
AMRN
$293M
$5.71M 0.37%
708
+40
+6% +$2.49K
XLV icon
36
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
$5.7M 0.37%
719
-8,729
-92% -$665K
ZGNX
37
PUT
DELISTED
Zogenix, Inc.
ZGNX
$5.55M 0.36%
3,825
+2,624
+218% +$33K
FOLD
38
CALL
DELISTED
Amicus Therapeutics
FOLD
$4.99M 0.33%
4,958
+605
+14% +$4.87K
BLUE
39
PUT
DELISTED
bluebird bio
BLUE
$4.97M 0.33%
37
+31
+517% +$37.4K
KYNB
40
CALL
Kyntra Bio
KYNB
$28.2M
$4.96M 0.32%
61
+23
+61% +$16K
GWPH
41
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.64M 0.3%
463
– –
PRTA icon
42
CALL
Prothena Corp
PRTA
$448M
$4.62M 0.3%
853
+193
+29% +$10.3K
SPNC
43
PUT
DELISTED
Spectranetics Corp
SPNC
$4.57M 0.3%
1,191
– –
SGEN
44
DELISTED
Seagen Inc. Common Stock
SGEN
$4.41M 0.29%
+85,162
New +$5.41M
AMAG
45
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$3.94M 0.26%
+2,140
New +$42.4K
CYTK icon
46
CALL
Cytokinetics
CYTK
$10.8B
$3.8M 0.25%
3,142
+1,119
+55% +$15.6K
BIOA
47
DELISTED
BioAmber Inc.
BIOA
$3.67M 0.24%
1,426,917
-33,942
-2% -$78K
INCY icon
48
CALL
Incyte
INCY
$26B
$3.55M 0.23%
282
-389
-58% -$49.5K
SPNC
49
DELISTED
Spectranetics Corp
SPNC
$3.48M 0.23%
90,715
+18,715
+26% +$540K
SGMO
50
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.42M 0.22%
3,892
+399
+11% +$2.56K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.